PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

Condition(s) targeted: Heart Failure, Congestive

Intervention: rolofylline (Drug); Comparator: Placebo (unspecified) (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: NovaCardia

Official(s) and/or principal investigator(s):
Barry Massie, MD, Study Chair, Affiliation: University of California San Francisco, USA
Christopher O'Connor, MD, Study Chair, Affiliation: Duke University, USA
Marco Metra, MD, Principal Investigator, Affiliation: University of Brescia, Italy

Overall contact:
Howard C Dittrich, MD, Phone: 858.523.4505, Email: howard_dittrich@merck.com

The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in subjects with acute heart failure syndrome and renal impairment.

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome:

effect on heart failure signs and symptoms

effect on renal function

Secondary outcome:

safety

within trial medical costs compared to placebo

Detailed description: Loop diuretics are generally first line therapy in patients hospitalized with acute heart failure syndrome (AHFS). Their use far exceeds that of vasoactive agents. Tubuloglomerular feedback (TGF) is the body's compensatory response to avoid excess fluid loss, and it is activated when elevated sodium concentrations in the distal tubule are detected. TGF is proposed as a contributing factor for the observed diuretic resistance that occurs in patients with heart failure. Higher doses of diuretics are required to overcome the decreased natriuresis and reduced RBF induced by TGF. Ultimately, this action creates a vicious cycle of worsening renal function and diminished diuretic effectiveness.

The primary pharmacologic rationale for the use of KW-3902 in subjects with AHFS is its mechanism of action as an adenosine A1 receptor antagonist. TGF promotes release of adenosine, and adenosine binding to A1 receptors causes vasoconstriction of the afferent arteriole, decreased RBF, and enhanced sodium reabsorption by the proximal tubule. This action results in a decrease in GFR, diminished renal function, and sodium and water retention. Blocking adenosine A1 receptors via a selective adenosine receptor antagonist may limit sodium reabsorption by the proximal tubules without triggering TGF. It promotes vasodilation of the afferent arteriole of the glomerulus, and thus, this strategy offers the potential to overcome diuretic resistance or enhance diuretic responsiveness. It may also reduce the need for increasing diuretic doses that have been associated with worse outcomes.

The objectives of this study are to evaluate the effect of KW-3902IV in addition to intravenous (IV) loop diuretics (such as furosemide) on heart failure signs and symptoms, renal function, and safety in subjects hospitalized with AHFS, volume overload, and renal impairment, and to estimate and compare within-trial medical resource utilization and direct medical costs between patients treated with KW-3902IV versus placebo.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. History of heart failure of at least 14 days duration for which diuretic therapy has been prescribed

2. Hospitalized for acute heart failure syndrome requiring IV diuretic therapy.

3. Impaired renal function

Exclusion Criteria:

1. Acute contrast induced nephropathy

2. Ongoing or planned IV therapy for heart failure with positive inotropic agents, vasopressors, vasodilators, or mechanical support with the exception of IV nitrates

3. BNP <500pg/mL or NT-pro-BNP <2000 pg/mL

4. Ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis

5. Severe pulmonary disease

6. Significant stenotic valvular disease

7. Heart transplant recipient or admitted for cardiac transplantation

8. Clinical evidence of acute coronary syndrome in the 2 weeks prior to screening

9. Heart failure due to significant arrhythmias

10. Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy.

11. Known hepatic impairment

12. Non-cardiac pulmonary edema, including suspected sepsis

13. Allergy to soybean oil or eggs

14. History of seizure

15. Stroke within 2 years

16. History of or current brain tumor of any etiology

17. Brain surgery within 2 years

18. Encephalitis/meningitis within 2 years

19. History of penetrating head trauma

20. Closed head injury with loss of consciousness (LOC) over 30 minutes within 2 years

21. History of, or at risk for, alcohol withdrawal seizures

22. Advanced Alzheimer's disease

23. Advanced multiple sclerosis

24. Hgb <8 g/dL, Hct <25%, or the need for a blood transfusion

25. Previous exposure to KW-3902

Howard C Dittrich, MD, Phone: 858.523.4505, Email: howard_dittrich@merck.com

Genk, Belgium; Recruiting

Aalst, Belgium; Recruiting

Huy, Belgium; Recruiting

Wilrijk, Belgium; Not yet recruiting

Antwerpen, Belgium; Recruiting

Halifax, Canada; Not yet recruiting

St. Johns, Canada; Recruiting

Praha, Czech Republic; Recruiting

Berlin, Germany; Recruiting

Regensburg, Germany; Recruiting

Langen, Germany; Recruiting

Aachen, Germany; Recruiting

Witten, Germany; Recruiting

Budapest, Hungary; Not yet recruiting

Pecs, Hungary; Not yet recruiting

Zeriffin, Israel; Recruiting

Jerusalem, Israel; Recruiting

Safed, Israel; Recruiting

Beer Sheva, Israel; Recruiting

Tel Aviv, Israel; Recruiting

Holon, Israel; Recruiting

Ashkelon, Israel; Recruiting

Trieste, Italy; Not yet recruiting

Rozzano Milano, Italy; Not yet recruiting

Naples, Italy; Not yet recruiting

Genova, Italy; Not yet recruiting

Heerlen, Netherlands; Not yet recruiting

Amsterdam, Netherlands; Recruiting

Hengelo, Netherlands; Not yet recruiting

Tilburg, Netherlands; Recruiting

Krakow, Poland; Not yet recruiting

Gdansk, Poland; Not yet recruiting

Warsaw, Poland; Not yet recruiting

Wroclaw, Poland; Not yet recruiting

Zielona Gora, Poland; Not yet recruiting

Moscow, Russian Federation; Recruiting

St Petersburg, Russian Federation; Recruiting

Yaroslavl, Russian Federation; Recruiting

Birmingham, Alabama, United States; Recruiting

Mobile, Alabama, United States; Recruiting

Edmonton, Alberta, Canada; Recruiting

Mesa, Arizona, United States; Recruiting

Victoria, British Columbia, Canada; Recruiting

Loma Linda, California, United States; Recruiting

San Francisco, California, United States; Not yet recruiting

Sacramento, California, United States; Recruiting

Denver, Colorado, United States; Recruiting

Washington, District of Columbia, United States; Recruiting

Miami, Florida, United States; Recruiting

Augusta, Georgia, United States; Recruiting

Atlanta, Georgia, United States; Not yet recruiting

Indianapolis, Indiana, United States; Recruiting

Iowa City, Iowa, United States; Recruiting

Baltimore, Maryland, United States; Recruiting

Annapolis, Maryland, United States; Not yet recruiting

Boston, Massachusetts, United States; Recruiting

West Roxbury, Massachusetts, United States; Not yet recruiting

St. Joseph, Michigan, United States; Not yet recruiting

Detroit, Michigan, United States; Recruiting

Minneapolis, Minnesota, United States; Recruiting

Tupelo, Mississippi, United States; Recruiting

St. Louis, Missouri, United States; Recruiting

Newark, New Jersey, United States; Recruiting

Elmhurst, New York, United States; Not yet recruiting

New York, New York, United States; Not yet recruiting

Winston-Salem, North Carolina, United States; Recruiting

Chapel Hill, North Carolina, United States; Recruiting

Greenville, North Carolina, United States; Recruiting

Columbus, Ohio, United States; Recruiting

Cincinnati, Ohio, United States; Not yet recruiting

Midwest City, Oklahoma, United States; Not yet recruiting

Toronto, Ontario, Canada; Not yet recruiting

Ottawa, Ontario, Canada; Recruiting

Sellersville, Pennsylvania, United States; Recruiting

Philadelphia, Pennsylvania, United States; Recruiting

Fleurimont, Quebec, Canada; Not yet recruiting

Montreal, Quebec, Canada; Recruiting

Charleston, South Carolina, United States; Not yet recruiting

Tullahoma, Tennessee, United States; Recruiting

Houston, Texas, United States; Recruiting

Danville, Virginia, United States; Recruiting

Madison, Wisconsin, United States; Recruiting

Starting date: August 2006
Ending date: November 2008
Last updated: January 28, 2008